The Intellectual Property & Science business of Thomson Reuters , the world’s leading provider of intelligent information for businesses and professionals, honored Amplimmune, Inc. and Medimmune for their work in pharmaceutical Mergers and Acquisitions (M&A), and Isis Pharmaceuticals and Biogen Idec for biopharmaceutical licensing with the Allicense 2014 Breakthrough Award for Deal of the Year .
The winners were announced Tuesday, April 29, after a public vote at 2014 Allicense , a prominent event connecting business development, licensing, and merger and acquisition (M&A) professionals throughout pharma, biotech and finance to discuss industry-wide challenges and collaborate on creating a roadmap for the future of pharmaceutical development. The annual award honors the top global deals in two categories: M&A and Biopharmaceutical Licensing. Five contenders in each category were nominated by Thomson Reuters deals analysts after a thorough analysis of information in Thomson Reuters Recap —the premier analysis tool for biopharmaceutical business deal making—and other criteria that examined hundreds of deals negotiated throughout 2013.